...to use the funds to advance Phase III testing for its mucositis candidate Validive clonidine lauriad...

...S.A. (Euronext:ONXEO; CSE:ONXEO) granted Monopar Therapeutics Inc. (Northbrook, Ill.) exclusive, worldwide rights to Validive clonidine lauriad...
...study. Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO), Paris, France Monopar Therapeutics Inc., Northbrook, Ill. Business: Other Chris Lieu Clonidine Lauriad Validive Monopar...

...Dara launched Oravig miconazole in the U.S. to treat oral candidiasis. Dara has U.S. rights to...
...U.S. to treat oral candidiasis. Dara has U.S. rights to the mucoadhesive buccal tablet of miconazole...
...the oncology market. The wholesale acquisition cost (WAC) of one 50 mg tablet is $54.43. Oravig...

...tied to sales milestones for oral mucositis drug Gelclair povidone and oropharyngeal candidiasis drug Oravig miconazole...
...half. Dara has rights to Gelclair from Helsinn Healthcare S.A. (Lugano, Switzerland) and rights to Oravig...

...Society of Clinical Oncology meeting in Chicago. Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO), Paris, France Product: Clonidine Lauriad...

...Onxeo granted Dara exclusive rights in the U.S. to commercialize Oravig miconazole, which is approved to...
...as part of a postmarketing commitment, which may provide for an expanded indication. Onxeo considered Oravig...
...partnered with Mission Pharmacal Co. (San Antonio, Texas) to co-promote the mucoadhesive buccal tablet of miconazole...

...deal comprised the four preclinical programs and SO-1105 , a mucoadhesive buccal tablet of miconazole. SO-1105...

...to treat hepatocellular carcinoma and plans to begin a Phase III trial of Validive clonidine Lauriad...

...BioAlliance granted EMS rights to commercialize Sitavig acyclovir Lauriad in Brazil. The mucoadhesive formulation of acyclovir...

...patients with head and neck cancer. BioAlliance Pharma S.A. (Euronext:BIO), Paris, France Product: Validive clonidine Lauriad...